FYLD | $41,000,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)
Helia Care, Inc. | $3,000,000 | (Feb 18, 2026)
Rapport Therapeutics
United States
- Boston, Massachusetts
- 08/03/2023
- Series A
- $100,000,000
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.
- Industry Biotechnology Research
- Website https://www.rapportrx.com/
- LinkedIn https://www.linkedin.com/company/rapport-therapeutics/
Dataro | $14,280,000 | (Feb 18, 2026)
Daffodil Health Corp | $16,300,000 | (Feb 18, 2026)
Sphinx(US) | $7,100,000 | (Feb 18, 2026)
Autosana (YC S25) | $3,200,000 | (Feb 18, 2026)
Certivo | $4,000,000 | (Feb 18, 2026)
GelMEDIX | $13,000,000 | (Feb 18, 2026)
QuadSci.ai | $8,000,000 | (Feb 18, 2026)
Breaker | $6,000,000 | (Feb 18, 2026)
Bland Company | $2,670,000 | (Feb 18, 2026)